ELVN
Enliven Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Enliven Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
No other changes.
No other changes.
Annual filing, covered
10-K parsed · Mar 3 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 3 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Enliven Therapeutics, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Enliven Therapeutics, Inc.'s 6 closest co-movers, none share that code.
+0.95%
vs ±11.2% implied · ×0.08
shaded = implied · ▲▼ = realized
Enliven Therapeutics, Inc.
45.50
+0.87 · +1.94%
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $508.8M | 12.45% | +46.80% |
| Orbimed | $343.9M | 8.42% | −14.86% |
| Polar Capital | $326.4M | 7.99% | +26.94% |
| BlackRockindex-like | $221.3M | 5.42% | +18.32% |
| Vestal Point Capital | $203.0M | 4.97% | +23.08% |
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $508.8M | 12.45% | +46.80% |
| Orbimed | $343.9M | 8.42% | −14.86% |
| Polar Capital | $326.4M | 7.99% | +26.94% |
| BlackRockindex-like | $221.3M | 5.42% | +18.32% |
| Vestal Point Capital | $203.0M | 4.97% | +23.08% |
Bull2
Bear2
—
—
Tall tick = annual report · Source: EDGAR
Expected move
Inputs8Q avg ±3.0%·×2.34·rich
straddle ±10.3%
spot 44.63exp Nov 20ATM strike 45ATM straddle 5.43IV 68%